Zurich Insurance Group Ltd FI cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 137,496 shares of the company’s stock after selling 13,243 shares during the period. Zurich Insurance Group Ltd FI’s holdings in Eli Lilly and were worth $11,316,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Airain ltd bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $567,000. Buckingham Asset Management LLC increased its position in shares of Eli Lilly and by 21.3% during the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after purchasing an additional 568 shares during the period. BSW Wealth Partners increased its position in shares of Eli Lilly and by 0.6% during the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after purchasing an additional 27 shares during the period. Sumitomo Life Insurance Co. increased its position in shares of Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after purchasing an additional 1,370 shares during the period. Finally, Mirador Capital Partners LP increased its position in shares of Eli Lilly and by 5.3% during the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after purchasing an additional 619 shares during the period. Institutional investors and hedge funds own 76.61% of the company’s stock.

Eli Lilly and Company (LLY) opened at $82.89 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The stock has a market capitalization of $91,269.77, a price-to-earnings ratio of 20.27, a PEG ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the firm posted $0.88 earnings per share. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

TRADEMARK VIOLATION NOTICE: “Zurich Insurance Group Ltd FI Lowers Stake in Eli Lilly and Company (LLY)” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/zurich-insurance-group-ltd-fi-lowers-stake-in-eli-lilly-and-company-lly/1715208.html.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 772,003 shares of company stock worth $64,837,441 in the last ninety days. 0.20% of the stock is currently owned by insiders.

Several analysts recently commented on LLY shares. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Leerink Swann boosted their price target on Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $89.76.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.